L&G Pharma Breakthrough

ETF description

The L&G Pharma Breakthrough ETF is designed to provide investors with exposure to innovative pharmaceutical and biotechnology companies that are at the forefront of medical research and drug development. By tracking the Solactive Pharma Breakthrough index, this ETF focuses on companies engaged in groundbreaking pharmaceutical advancements and the development of new treatments, aiming to capture the growth potential in the rapidly evolving healthcare sector.

Issuer details

Legal & General Investment Management (LGIM) is one of Europe’s largest asset managers and a subsidiary of Legal & General Group plc. With over £1.5 trillion in assets under management as of June 2024. Established in 1836, LGIM has a long history and is known for its strong focus on index investing, providing investors with cost‑effective and diversified exposure to various markets. LGIM is also recognized for its innovative ESG integration across its investment strategies and expertise in liability‑driven investment (LDI) solutions. Notable ETFs include the L&G Global Technology Leaders UCITS ETF and the L&G Cyber Security UCITS ETF, reflecting LGIM’s commitment to providing access to innovative and thematic investment themes. LGIM offers a range of investment solutions and covers various market segments.

Index details

The Pharma Breakthrough index provides comprehensive exposure to the pharmaceutical sector, focusing on companies that are leading the way in drug development and medical breakthroughs. It serves as a valuable tool for investors seeking to benefit from the advancements in healthcare while achieving diversification across various therapeutic areas. The index’s focus on innovation and market capitalization ensures a balanced representation of the pharmaceutical market, making it an essential benchmark for evaluating the performance of investments in pharmaceutical innovations globally.